{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:18:33Z","timestamp":1786997913084,"version":"build-2736575974"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["2018ZX10721202"],"award-info":[{"award-number":["2018ZX10721202"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.vaccine.2025.127596","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T08:50:46Z","timestamp":1754902246000},"page":"127596","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Duration of immunogenicity of four triple doses and four standard doses hepatitis B vaccine in adults infected with human immunodeficiency virus: A one-year follow-up study in China"],"prefix":"10.1016","volume":"62","author":[{"given":"Linying","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaosheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyuan","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangle","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yandi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinbo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenli","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyong","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuzhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongliang","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2025.127596_bb0005","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.853346","article-title":"HIV infection predisposes to increased chances of HBV infection: current understanding of the mechanisms favoring HBV infection at each clinical stage of HIV infection","volume":"13","author":"Zaongo","year":"2022","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.vaccine.2025.127596_bb0010","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/cid\/ciz1170","article-title":"Global burden of hepatitis B infection in people living with human immunodeficiency virus: a systematic review and meta-analysis","volume":"71","author":"Leumi","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127596_bb0015","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/jvh.13217","article-title":"Prevalence and burden of HBV co-infection among people living with HIV: a global systematic review and meta-analysis","volume":"27","author":"Platt","year":"2020","journal-title":"J Viral Hepat"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127596_bb0020","first-page":"14","article-title":"Chronic hepatitis B and HIV coinfection","volume":"31","author":"Corcorran","year":"2023","journal-title":"Top Antivir Med"},{"issue":"6","key":"10.1016\/j.vaccine.2025.127596_bb0025","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.jhep.2005.01.022","article-title":"Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol","volume":"42","author":"Salmon-Ceron","year":"2005","journal-title":"J Hepatol"},{"issue":"15","key":"10.1016\/j.vaccine.2025.127596_bb0030","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1097\/QAD.0000000000001574","article-title":"HIV-hepatitis B virus coinfection: epidemiology, pathogenesis, and treatment","volume":"31","author":"Singh","year":"2017","journal-title":"AIDS"},{"issue":"10","key":"10.1016\/j.vaccine.2025.127596_bb0035","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2165\/00003495-200363100-00006","article-title":"Recombinant hepatitis B vaccine (Engerix-B\u00ae): a review of its immunogenicity and protective efficacy against hepatitis B","volume":"63","author":"Keating","year":"2003","journal-title":"Drugs"},{"issue":"14","key":"10.1016\/j.vaccine.2025.127596_bb0040","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1001\/jama.2011.351","article-title":"Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial","volume":"305","author":"Launay","year":"2011","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.vaccine.2025.127596_bb0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0080409","article-title":"Comparison of immunogenicity and safety of four doses and four double doses vs. standard doses of hepatitis B vaccination in HIV-infected adults: a randomized, controlled trial","volume":"8","author":"Chaiklang","year":"2013","journal-title":"PloS One"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127596_bb0050","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/0956462412472309","article-title":"Does increased hepatitis B vaccination dose lead to a better immune response in HIV-infected patients than standard dose vaccination: a meta-analysis?","volume":"24","author":"Ni","year":"2013","journal-title":"Int J STD AIDS"},{"issue":"11","key":"10.1016\/j.vaccine.2025.127596_bb0055","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1473-3099(15)00220-0","article-title":"Safety and immunogenicity of double-dose versus standard-dose hepatitis B revaccination in non-responding adults with HIV-1 (ANRS HB04 B-BOOST): a multicentre, open-label, randomised controlled trial","volume":"15","author":"Rey","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2025.127596_bb0060","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/jamainternmed.2016.0741","article-title":"Long-term immune response to hepatitis B virus vaccination regimens in adults with human immunodeficiency virus 1 secondary analysis of a randomized clinical trial","volume":"176","author":"Launay","year":"2016","journal-title":"JAMA Intern Med"},{"issue":"24","key":"10.1016\/j.vaccine.2025.127596_bb0065","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1016\/j.vaccine.2020.04.022","article-title":"Systematic review and meta-analysis of immune response of double dose of hepatitis B vaccination in HIV-infected patients","volume":"38","author":"Lee","year":"2020","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2025.127596_bb0070","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.vaccine.2012.12.047","article-title":"Long-term response rates of successful hepatitis B vaccination in HIV-infected patients","volume":"31","author":"Lopes","year":"2013","journal-title":"Vaccine"},{"issue":"27","key":"10.1016\/j.vaccine.2025.127596_bb0075","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1016\/j.vaccine.2021.05.044","article-title":"Immunogenicity and persistence of high-dose recombinant hepatitis B vaccine in adults infected with human immunodeficiency virus in China: a randomized, double-blind, parallel controlled trial","volume":"39","author":"Feng","year":"2021","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127596_bb0080","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12981-019-0249-8","article-title":"Higher rate of long-term serologic response of four double doses vs. standard doses of hepatitis B vaccination in HIV-infected adults: 4-year follow-up of a randomised controlled trial","volume":"16","author":"Chaiwarith","year":"2019","journal-title":"AIDS Res Ther"},{"issue":"12","key":"10.1016\/j.vaccine.2025.127596_bb0085","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.3390\/vaccines9121484","article-title":"Undetectable anti-HBs antibodies: need of a booster dose for HIV-1-infected individuals","volume":"9","author":"Bekele","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"12","key":"10.1016\/j.vaccine.2025.127596_bb0090","first-page":"938","article-title":"The guidelines of prevention and treatment for chronic hepatitis B (2019 version)","volume":"27","author":"Chinese Society of Infectious Diseases","year":"2019","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"issue":"6","key":"10.1016\/j.vaccine.2025.127596_bb0095","first-page":"1425","article-title":"Guidelines for the prevention and treatment of chronic hepatitis B (version 2022)","volume":"11","author":"You","year":"2023","journal-title":"J Clin Transl Hepatol"},{"issue":"6","key":"10.1016\/j.vaccine.2025.127596_bb0100","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1080\/14760584.2022.2056024","article-title":"Immunogenicity and safety of 4 intramuscular standard-dose and high-dose hepatitis B vaccine in people living with HIV: a randomized, parallel-controlled trial","volume":"21","author":"Feng","year":"2022","journal-title":"Expert Rev Vaccines"},{"issue":"8543","key":"10.1016\/j.vaccine.2025.127596_bb0105","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/S0140-6736(87)92176-3","article-title":"Timing of hepatitis B revaccination in healthy adults","volume":"1","author":"Laplanche","year":"1987","journal-title":"Lancet"},{"issue":"9203","key":"10.1016\/j.vaccine.2025.127596_bb0110","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0140-6736(99)07239-6","article-title":"Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B immunity","volume":"355","author":"Consensus","year":"2000","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127596_bb0115","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/00001648-199605000-00012","article-title":"Confidence intervals for measures of interaction","volume":"7","author":"Assmann","year":"1996","journal-title":"Epidemiology"},{"issue":"7","key":"10.1016\/j.vaccine.2025.127596_bb0120","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s10654-005-7835-x","article-title":"Calculating measures of biological interaction","volume":"20","author":"Andersson","year":"2005","journal-title":"Eur J Epidemiol"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127596_bb0125","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/infdis\/jiv748","article-title":"Antibody levels and protection after hepatitis B vaccine: results of a 30-year follow-up study and response to a booster dose","volume":"214","author":"Bruce","year":"2016","journal-title":"J Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2025.127596_bb0130","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1089\/aid.2017.0070","article-title":"Hepatitis B virus vaccination in HIV: immunogenicity and persistence of seroprotection up to 7 years following a primary immunization course","volume":"34","author":"Nicolini","year":"2018","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"41","key":"10.1016\/j.vaccine.2025.127596_bb0135","doi-asserted-by":"crossref","first-page":"5973","DOI":"10.1016\/j.vaccine.2012.07.028","article-title":"Vaccination against hepatitis B with 4-double doses increases response rates and antibodies titers in HIV-infected adults","volume":"30","author":"Potsch","year":"2012","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2025.127596_bb0140","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/15321819.2018.1509871","article-title":"Relationship between Th1 and Th2 cytokine serum levels and immune response to hepatitis B vaccination among Egyptian health care workers","volume":"39","author":"Sabry","year":"2018","journal-title":"J Immunoassay Immunochem"},{"issue":"9","key":"10.1016\/j.vaccine.2025.127596_bb0145","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1080\/21645515.2021.1895603","article-title":"Predicting related factors of immunological response to hepatitis B vaccine in hemodialysis patients based on integration of decision tree classification and logistic regression","volume":"17","author":"Feng","year":"2021","journal-title":"Hum Vaccin Immunother"},{"issue":"11","key":"10.1016\/j.vaccine.2025.127596_bb0150","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1080\/14760584.2022.2112951","article-title":"Duration of immunogenicity of high-dose and prolonged-schedule hepatitis B vaccine among patients with chronic kidney disease: a one year follow-up study in China","volume":"21","author":"Han","year":"2022","journal-title":"Expert Rev Vaccines"},{"issue":"46","key":"10.1016\/j.vaccine.2025.127596_bb0155","doi-asserted-by":"crossref","first-page":"6302","DOI":"10.1016\/j.vaccine.2017.09.076","article-title":"Hepatitis B vaccine and the need for a booster dose after primary vaccination","volume":"35","author":"Pileggi","year":"2017","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127596_bb0160","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.cellimm.2011.10.009","article-title":"Gender effect on in vitro lymphocyte subset levels of healthy individuals","volume":"272","author":"Abdullah","year":"2012","journal-title":"Cell Immunol"},{"issue":"10","key":"10.1016\/j.vaccine.2025.127596_bb0165","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nri.2016.90","article-title":"Sex differences in immune responses","volume":"16","author":"Klein","year":"2016","journal-title":"Nat Rev Immunol"},{"issue":"49\u201350","key":"10.1016\/j.vaccine.2025.127596_bb0170","doi-asserted-by":"crossref","first-page":"7124","DOI":"10.1016\/j.vaccine.2006.06.079","article-title":"Humoral response to hepatitis B vaccination and its relationship with T CD45RA+ (na\u00efve) and CD45RO+ (memory) subsets in HIV-1-infected subjects","volume":"24","author":"Veiga","year":"2006","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2025.127596_bb0175","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/cid\/cit937","article-title":"Long-term immune responses to vaccination in HIV-infected patients: a systematic review and meta-analysis","volume":"58","author":"Kern\u00e9is","year":"2014","journal-title":"Clin Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2500893X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2500893X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T03:23:47Z","timestamp":1766546627000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2500893X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":35,"alternative-id":["S0264410X2500893X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127596","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Duration of immunogenicity of four triple doses and four standard doses hepatitis B vaccine in adults infected with human immunodeficiency virus: A one-year follow-up study in China","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127596","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"127596"}}